Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. 2009

Yiqun Gu, and Xiaowei Liang, and Weixiong Wu, and Minli Liu, and Shuxiu Song, and Lifa Cheng, and Liwei Bo, and Chengliang Xiong, and Xinghai Wang, and Xiaozhang Liu, and Lin Peng, and Kangshou Yao
Department of Male Clinic Research, National Research Institute for Family Planning, 12 Da Hui Si Road, Haidian District, Beijing 100081, China. ygu90@yahoo.cn

BACKGROUND Hormonal male contraceptive regimens effectively and reversibly suppress sperm production, but there are few large-scale efficacy studies. OBJECTIVE The safety, contraceptive efficacy, reversibility, and feasibility of injectable testosterone undecanoate (TU) in tea seed oil as a hormonal male contraceptive was assessed. METHODS This was a multicenter, phase III, contraceptive efficacy clinical trial. METHODS A total of 1045 healthy fertile Chinese men were recruited throughout China into the study. METHODS Injections of 500 mg TU were administered monthly for 30 months. A definition of severe oligozoospermia (< or =1 x 10(6)/ml) was used as a criterion of spermatogenic suppression and as the threshold for entering the contraceptive efficacy phase. METHODS The primary outcome was pregnancy rate in the partner. Other outcomes include: semen parameters, testis volumes, reproductive hormone levels, and safety laboratory tests. RESULTS Forty-three participants (4.8%) did not achieve azoospermia or severe oligozoospermia within the 6-month suppression phase. A total of 855 participants entered into the efficacy phase, and 733 participants completed monthly TU treatment and follow-up. There were nine pregnancies in 1554.1 person-years of exposure in the 24-month efficacy phase for a cumulative contraceptive failure rate of 1.1 per 100 men. The combined method failure rate was 6.1%, comprising 4.8% with inadequate suppression and 1.3% with postsuppression sperm rebound. No serious adverse events were reported. Spermatogenesis returned to the normal fertile reference range in all but two participants. CONCLUSIONS Monthly injection of 500 mg TU provides safe, effective, reversible, and reliable contraception in a high proportion of healthy fertile Chinese men.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D002681 China A country spanning from central Asia to the Pacific Ocean. Inner Mongolia,Manchuria,People's Republic of China,Sinkiang,Mainland China
D003267 Contraception Prevention of CONCEPTION by blocking fertility temporarily, or permanently (STERILIZATION, REPRODUCTIVE). Common means of reversible contraception include NATURAL FAMILY PLANNING METHODS; CONTRACEPTIVE AGENTS; or CONTRACEPTIVE DEVICES. Birth Control,Contraceptive Methods,Female Contraception,Fertility Control,Inhibition of Fertilization,Male Contraception,Contraception, Female,Contraception, Male,Contraceptions, Female,Contraceptions, Male,Contraceptive Method,Female Contraceptions,Fertilization Inhibition,Male Contraceptions
D003272 Contraceptive Agents, Male Chemical substances or agents with contraceptive activity in males. Use for male contraceptive agents in general or for which there is no specific heading. Male Contraceptive,Contraceptives, Male,Agents, Male Contraceptive,Contraceptive, Male,Male Contraceptive Agents,Male Contraceptives
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Yiqun Gu, and Xiaowei Liang, and Weixiong Wu, and Minli Liu, and Shuxiu Song, and Lifa Cheng, and Liwei Bo, and Chengliang Xiong, and Xinghai Wang, and Xiaozhang Liu, and Lin Peng, and Kangshou Yao
February 2003, The Journal of clinical endocrinology and metabolism,
Yiqun Gu, and Xiaowei Liang, and Weixiong Wu, and Minli Liu, and Shuxiu Song, and Lifa Cheng, and Liwei Bo, and Chengliang Xiong, and Xinghai Wang, and Xiaozhang Liu, and Lin Peng, and Kangshou Yao
October 1999, The Journal of clinical endocrinology and metabolism,
Yiqun Gu, and Xiaowei Liang, and Weixiong Wu, and Minli Liu, and Shuxiu Song, and Lifa Cheng, and Liwei Bo, and Chengliang Xiong, and Xinghai Wang, and Xiaozhang Liu, and Lin Peng, and Kangshou Yao
August 2006, Human reproduction (Oxford, England),
Yiqun Gu, and Xiaowei Liang, and Weixiong Wu, and Minli Liu, and Shuxiu Song, and Lifa Cheng, and Liwei Bo, and Chengliang Xiong, and Xinghai Wang, and Xiaozhang Liu, and Lin Peng, and Kangshou Yao
January 1998, Journal of andrology,
Yiqun Gu, and Xiaowei Liang, and Weixiong Wu, and Minli Liu, and Shuxiu Song, and Lifa Cheng, and Liwei Bo, and Chengliang Xiong, and Xinghai Wang, and Xiaozhang Liu, and Lin Peng, and Kangshou Yao
March 2004, Asian journal of andrology,
Yiqun Gu, and Xiaowei Liang, and Weixiong Wu, and Minli Liu, and Shuxiu Song, and Lifa Cheng, and Liwei Bo, and Chengliang Xiong, and Xinghai Wang, and Xiaozhang Liu, and Lin Peng, and Kangshou Yao
January 2004, Journal of andrology,
Yiqun Gu, and Xiaowei Liang, and Weixiong Wu, and Minli Liu, and Shuxiu Song, and Lifa Cheng, and Liwei Bo, and Chengliang Xiong, and Xinghai Wang, and Xiaozhang Liu, and Lin Peng, and Kangshou Yao
February 2002, The Journal of clinical endocrinology and metabolism,
Yiqun Gu, and Xiaowei Liang, and Weixiong Wu, and Minli Liu, and Shuxiu Song, and Lifa Cheng, and Liwei Bo, and Chengliang Xiong, and Xinghai Wang, and Xiaozhang Liu, and Lin Peng, and Kangshou Yao
September 2014, Expert opinion on pharmacotherapy,
Yiqun Gu, and Xiaowei Liang, and Weixiong Wu, and Minli Liu, and Shuxiu Song, and Lifa Cheng, and Liwei Bo, and Chengliang Xiong, and Xinghai Wang, and Xiaozhang Liu, and Lin Peng, and Kangshou Yao
May 2015, European journal of endocrinology,
Yiqun Gu, and Xiaowei Liang, and Weixiong Wu, and Minli Liu, and Shuxiu Song, and Lifa Cheng, and Liwei Bo, and Chengliang Xiong, and Xinghai Wang, and Xiaozhang Liu, and Lin Peng, and Kangshou Yao
September 2008, Journal of proteome research,
Copied contents to your clipboard!